智通财经APP讯，艾迪药业(688488.SH)发布2025年度业绩快报，报告期内，公司营业总收入7.21亿元， 较上年同期增加72.49%。归属于母公司所有者的净利润-1,973.37万元，较上年同期相比，亏损幅度同比 下降86.02%。 主要原因如下：(1)报告期内因抗HIV创新药收入的增加、合并南大药业的经营数据等原因，导致主营业 务毛利较上年同期增加了约25,500万元;(2)报告期内因公司加大新药推广力度、合并南大药业的经营数 据等原因，本期销售费用支出较上年同期增加了约9,200万元;(3)报告期内公司因市场开拓与预期变化趋 于平稳，本期的资产减值损失较上年同期减少了约4,800万元。 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2026-020 江苏艾迪药业集团股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以江苏艾迪药业集团股份有限公司（以下简称"公司"）2025 年 年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 72,066.96 | 41,780.47 | 72.49 | | 营业利润 | 4,774.60 | -16,446.54 | 不适用 | | 利润总额 | 2,430.42 | -16,599.70 | 不适用 | | 归属于母公司所有者的净利润 | -1,973.37 | -14,120.43 | 不适用 | | 归属于母公司所有者的扣除非 | -2,092.72 | -1 ...

格隆汇2月24日丨艾迪药业(688488.SH)公布2025年度业绩快报，报告期内，公司营业总收入7.21亿元， 较上年同期增加72.49%；营业利润4774.60万元，较上年同期相比，将扭亏为盈；利润总额2430.42万 元，较上年同期相比，将扭亏为盈；归属于母公司所有者的净利润-1973.37万元，较上年同期相比，亏 损幅度同比下降86.02%；归属于母公司所有者的扣除非经常性损益的净利润-2092.72 万元，较上年同期 相比，亏损幅度同比下降85.90%。报告期末，公司总资产19.16亿元，较期初增加2.50%；归属于母公司 的所有者权益9.64亿元，较期初减少1.67%。 2025 年年度公司实现归属于母公司所有者的净利润为-1973.37万元，较上年度相比，亏损幅度同比下降 86.02%，主要原因如下：(1)报告期内因抗 HIV 创新药收入的增加、合并南大药业的经营数据等原因， 导致主营业务毛利较上年同期增加了约2.55亿元；(2)报告期内因公司加大新药推广力度、合并南大药业 的经营数据等原因，本期销售费用支出较上年同期增加了约9200.00万元；(3)报告期内公司因市场开拓 与预期变化趋于平稳， ...

艾迪药业发布业绩快报，2025年度营业总收入7.21亿元，同比增长72.49%；净利润亏损1973.37万元， 上年同期亏损1.41亿元。报告期内因抗HIV创新药收入的增加、合并南大药业的经营数据等原因，导致 主营业务毛利较上年同期增加了约2.55亿元；报告期内因公司加大新药推广力度、合并南大药业的经营 数据等原因，本期销售费用支出较上年同期增加了约9200万元；报告期内公司因市场开拓与预期变化趋 于平稳，本期的资产减值损失较上年同期减少了约4800万元。 ...

2025 年年度公司实现归属于母公司所有者的净利润为-1973.37万元，较上年度相比，亏损幅度同比下降 86.02%，主要原因如下：(1)报告期内因抗 HIV 创新药收入的增加、合并南大药业的经营数据等原因， 导致主营业务毛利较上年同期增加了约2.55亿元；(2)报告期内因公司加大新药推广力度、合并南大药业 的经营数据等原因，本期销售费用支出较上年同期增加了约9200.00万元；(3)报告期内公司因市场开拓 与预期变化趋于平稳，本期的资产减值损失较上年同期减少了约4800.00万元。 格隆汇2月24日丨艾迪药业(688488.SH)公布2025年度业绩快报，报告期内，公司营业总收入7.21亿元， 较上年同期增加72.49%；营业利润4774.60万元，较上年同期相比，将扭亏为盈；利润总额2430.42万 元，较上年同期相比，将扭亏为盈；归属于母公司所有者的净利润-1973.37万元，较上年同期相比，亏 损幅度同比下降86.02%；归属于母公司所有者的扣除非经常性损益的净利润-2092.72 万元，较上年同期 相比，亏损幅度同比下降85.90%。报告期末，公司总资产19.16亿元，较期初增加2.50%；归属于 ...

Group 1: Weichuang Electric / Automation Equipment - The company is strengthening collaborations to promote technological innovation and market expansion in the robot-driven component business [4] - Plans to establish a joint venture in Thailand with Zhejiang Rongtai to expand the smart robot electromechanical integration market, with both parties holding 50% shares [4] - The company aims to deepen industry demand and continue global expansion, focusing on regions like Asia, Africa, and Latin America while enhancing product offerings [5] - Revenue projections for 2025-2027 are estimated at 1.977 billion, 2.444 billion, and 3.108 billion yuan, with net profits of 288 million, 346 million, and 419 million yuan respectively [6] Group 2: Lenovo Group / Computer Equipment - Lenovo reported FY2026Q3 revenue of approximately 22.204 billion USD, an 18% year-on-year increase, with a net profit of 546 million USD, down 21% year-on-year [7][8] - The adjusted net profit increased by 36% year-on-year, driven by efficiency optimization and a high-end product mix [8] - The Infrastructure Solutions Group (ISG) is undergoing strategic restructuring, expected to accelerate the return to profitability in FY2027 [9] Group 3: Shipping and Ports Industry - National import and export total reached 45.47 trillion yuan in 2025, with a 3.8% year-on-year growth [13] - Container throughput at major coastal ports reached 31.198 million TEUs, a 7% year-on-year increase [15] - The Baltic Dry Index (BDI) rose by 135.95% year-on-year, indicating a significant increase in dry bulk shipping rates [19] Group 4: Google-A / Overseas - Google reported Q4 2025 revenue of 113.828 billion USD, an 18% year-on-year increase, with a net profit of 33.455 billion USD, up 30% year-on-year [25] - Search advertising revenue grew by 17% year-on-year, driven by AI innovations enhancing user experience and monetization efficiency [26] - Google Cloud revenue surged by 48% year-on-year, reaching 17.7 billion USD, with a significant increase in annual recurring revenue [27] Group 5: Yutong Technology / Packaging Printing - The company plans to acquire 51% of Huayan Technology for 449 million yuan, aiming to enhance its capabilities in precision manufacturing [32][34] - The acquisition is expected to leverage industry synergies and empower the second growth curve, focusing on high-profile clients like Google and Samsung [34] - Revenue projections for 2025-2027 are estimated at 19.069 billion, 21.001 billion, and 23.077 billion yuan, with net profits of 1.608 billion, 1.798 billion, and 1.980 billion yuan respectively [34] Group 6: NetEase-S / Gaming - NetEase reported Q4 2025 revenue of 27.5 billion yuan, a 3% year-on-year increase, with a net profit of 6.2 billion yuan, down 28.8% year-on-year [36][37] - The gaming segment showed resilience with a revenue of 22 billion yuan, driven by strong performance from popular IPs and new game launches [38] - The company is focusing on AI-driven strategies to enhance operational efficiency and optimize its business structure [39] Group 7: Aidi Pharmaceutical / Biopharmaceuticals - The company is advancing its international product launch and received GMP certification from Tanzania, facilitating entry into the African market [43] - Revenue for 2025 is projected at 721 million yuan, a 72.57% year-on-year increase, with a focus on HIV innovative drug sales [43] - Multiple new drug pipelines are actively progressing, with significant clinical trial approvals received [44] Group 8: Meituan-W / Local Life Services - Meituan is projected to achieve total revenue of 916 billion yuan in Q4 2025, with a core local business revenue of 648 billion yuan, reflecting a competitive landscape [45][46] - The company is strategically increasing investments in marketing and rider incentives to enhance operational efficiency amid fierce competition [46] - Long-term growth potential is anticipated through refined operations in instant delivery and overseas expansion [49] Group 9: Huahong Semiconductor / Semiconductors - Huahong Semiconductor reported Q4 2025 revenue of 660 million USD, a 22.4% year-on-year increase, with a wafer shipment of 1.45 million pieces [50]

Company Overview - Eddie Pharmaceutical Co., Ltd. is located in Yangzhou, Jiangsu Province, and was established on December 15, 2009. The company went public on July 20, 2020. Its main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of the company includes: human-derived proteins 41.11%, new drugs 35.69%, diagnostic equipment, reagents, and others 13.62%, generic drugs 9.47%, and other supplementary products 0.11% [1] Stock Performance - On February 13, Eddie Pharmaceutical's stock rose by 5.67%, reaching a price of 17.71 yuan per share, with a trading volume of 42.1543 million yuan and a turnover rate of 0.58%. The total market capitalization is 7.452 billion yuan [1] Shareholder Information - Among the top ten circulating shareholders of Eddie Pharmaceutical, one fund under Penghua Fund ranks as a significant shareholder. Penghua Medical Technology Stock A (001230) reduced its holdings by 2.68 million shares in the third quarter, now holding 4.1255 million shares, which accounts for 0.98% of the circulating shares [2] - As of the latest data, Penghua Medical Technology Stock A has a total asset size of 1.721 billion yuan, with a year-to-date return of 3.02%, ranking 3882 out of 5569 in its category. Over the past year, it achieved a return of 70.19%, ranking 227 out of 4295 [2] Fund Management - The fund manager of Penghua Medical Technology Stock A is Jin Xiaofei, who has been in the position for 9 years and 237 days. The total asset size of the fund is 5.331 billion yuan, with the best fund return during his tenure being 243.33% and the worst being -0.92% [3]

Core Viewpoint - Eddie Pharmaceuticals announced the approval of a plan to use up to 100 million yuan of idle raised funds to temporarily supplement working capital, specifically for operations related to its main business [1] Group 1 - The third meeting of the third board of directors approved the fund usage [1] - The funds will be used for a period not exceeding 12 months from the date of board approval [1] - No shareholder meeting approval is required for this decision [1]

Group 1 - The company announced plans to use up to 100 million yuan of temporarily idle raised funds for cash management [1] - The investment period is set from April 14, 2026, to April 13, 2027, allowing for rolling purchases of principal-protected structured deposits and similar products [1] - The generated income will be used to supplement cash flow and cover fundraising gaps, with no need for shareholder meeting approval [1]

证券代码：688488 证券简称：艾迪药业 公告编号：2026-018 江苏艾迪药业集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述募集资金已于 2020 年 7 月 13 日全部到位，容诚会计师事务所（特殊普 通合伙）对本次发行募集资金的到账情况进行了审验，并出具了容诚验字[2020] 210Z0012 号《验资报告》。本公司对募集资金采取了专户存储制度。 1 二、募集资金投资项目的基本情况 公司募投项目之原料药生产研发及配套设施项目、艾邦德®（艾诺韦林片） Ⅲ期临床及上市后研究项目、ACC008 Ⅲ/Ⅳ期临床项目已结项，其余募投项目 基本情况如下： | 序号 | 项目名称 | 项目内容 | 募集资金承诺投资总 | | | --- | --- | --- | --- | --- | | | | | 额（万元） | | | 1 | 创新药研发及研发技 | 整合酶抑制剂药物研发及其临床 研究项目 | 15,446.99 | | | | 术中心大楼购买项目 ...